E
GALT icon

Ergoteles’s Galectin Therapeutics GALT Stock Holding History

Ergoteles’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-136,320
Closed -$529K – 1366
2021
Q3 		$529K Sell
136,320
-2,861
-2% -$9.7K 0.02% 557
2021
Q2 		$445K Buy
+139,181
New +$495K 0.01% 868

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ergoteles's GALT Position: Q4 2021 in Review

Ergoteles sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 136,320 shares — an estimated $529K sold.

Ergoteles first reported a position in GALT in Q2 2021 and held it in 2 quarters. The position peaked at $529K in Q3 2021. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

  • Ergoteles reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 136,320 Galectin Therapeutics shares in Q4 2021, an estimated $529K.
  • Ergoteles first reported a position in Galectin Therapeutics in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Galectin Therapeutics position peaked at $529K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.